Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Corporation announced preclinical data demonstrating that atebimetinib, a MEK inhibitor, enhances PD-1 checkpoint blockade in RAS mutant tumor models. The findings support the company's plans to conduct a Phase 2 study combining atebimetinib with PD-1 blockade in lung cancer patients. The poster will be presented at the SITC 41st Annual Meeting in November 2026.